Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Simulated model could target myeloma treatment

Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Key clinical point: A simulated treatment model estimated the benefit of using certain drugs in multiple myeloma treatment.

Major finding: Bortezomib would yield a 100% greater-than-average progression-free survival benefit in 20% of patients; lenalidomide would yield a 200% greater-than-average PFS benefit in 31% of patients.

Study details: Three randomized, phase 3 clinical trials of 910 patients with multiple myeloma were used for the simulation.

Disclosures: The Van Herk Fellowship provided support. The lenalidomide dataset was created as part of the Multiple Myeloma Research Foundation Personalized Medicine Initiative. Dr. Ubels and one coinvestigator are employees of SkylineDx; another coinvestigator served on its advisory board. The others reported having no relevant conflicts of interest.

Read the article.


Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

This Week's Must Reads

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.

New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Must Reads in Multiple Myeloma

Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.

Myeloma PFS boosted by elotuzumab add-on therapy, Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Lenalidomide-refractory MM responds to triple therapy, Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).

Added pomalidomide reduced risk of progression, death in myeloma, Richardson PG et al. ASCO 2018, Abstract 8001.